Tumors of younger patients with NSCLC had distinct genomic profiles with more targetable alterations, but lower mutational burden and immunogenicity compared to older patient tumors.
The study found that brain metastases in melanoma had a weaker immune response compared to primary skin, lymph node, and other metastatic sites, suggesting reduced immune cell infiltration and expression of immune checkpoint inhibitor targets.
Metastatic triple-negative breast cancer (TNBC) exhibits increased inflammation and higher expression of checkpoint targets compared to non-TNBC cases, with a paradoxical finding that lower PD-L1 expression is associated with better overall survival.
